A Practical Guide for Treatment of Rapidly Progressive ADPKD with Tolvaptan.

ABSTRACT: In the past, the treatment of autosomal dominant polycystic kidney disease (ADPKD) has been limited to the management of its symptoms and complications. Recently, the US Food and Drug Administration (FDA) approved tolvaptan as the first drug treatment to slow kidney function decline in adults at risk of rapidly progressing ADPKD. Full prescribing information approved by the FDA provides helpful guidelines but does not address practical questions that are being raised by nephrologists, internists, and general practitioners taking care of patients with ADPKD, and by the patients themselves. In this review, we provide practical guidance and discuss steps that require consideration before and after prescribing tolvaptan to patients with ADPKD to ensure that this treatment is implemented safely

SUBMITTER: Chebib FT 

PROVIDER: S-EPMC6171265 | biostudies-literature | 2018 Oct

REPOSITORIES: biostudies-literature